J. Fang

发表

Open-label, Multicenter, Phase II Study of RC48-ADC, a HER2-Targeting Antibody–Drug Conjugate, in Patients with Locally Advanced or Metastatic Urothelial Carcinoma

Jiyan Liu, J. Ying, X. Yao, 2020, Clinical Cancer Research.

Phase I study of the recombinant humanized anti-HER2 monoclonal antibody–MMAE conjugate RC48-ADC in patients with HER2-positive advanced solid tumors

Y. Ba, Yingying Xu, L. Shen, 2021, Gastric Cancer.

A phase II study of efficacy and safety of RC48-ADC in patients with locally advanced or metastatic HER2-overexpressing gastric or gastroesophageal junction cancers.

Y. Ba, Jianming Xu, Jia Wei, 2020 .

Efficacy and safety of a novel anti‐HER2 therapeutic antibody RC48 in patients with HER2‐overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single‐arm phase II study

Y. Ba, Jianming Xu, T. Deng, 2021, Cancer communications.

Phase II study of epirubicin plus oxaliplatin and infusional 5-fluorouracil as first-line combination therapy in patients with metastatic or advanced gastric cancer

P. Shen, Bo Mou, N. Xu, 2007, Anti-cancer drugs.

An open-label, multicenter, phase Ib study to evaluate RC48-ADC in patients with HER2-positive metastatic breast cancer.

Bing-he Xu, Qingyuan Zhang, Jiayu Wang, 2018 .

A phase II study of RC48-ADC in HER2-positive patients with locally advanced or metastatic urothelial carcinoma.

Jiyan Liu, X. Yao, Yanxia Shi, 2019, Journal of Clinical Oncology.

Assessment of the expression pattern of HER2 and its correlation with HER2-targeting antibody-drug conjugate therapy in urothelial cancer

J. Ying, Yanxia Shi, Y. Ling, 2023, Journal of the National Cancer Center.

RC48-ADC, a HER2-targeting antibody-drug conjugate, in patients with HER2-positive and HER2-low expressing advanced or metastatic breast cancer: A pooled analysis of two studies.

Yang Luo, Bing-he Xu, Jifeng Feng, 2021 .

An open-label, single-arm, multicenter, phase II study of RC48-ADC to evaluate the efficacy and safety of subjects with HER2 overexpressing locally advanced or metastatic urothelial cancer (RC48-C009).

Jiyan Liu, Shiying Yu, J. Ying, 2021 .

Safety, pharmacokinetics, and efficacy of RC48-ADC in a phase I study in patients with HER2-overexpression advanced solid cancer.

L. Shen, J. Gong, J. Fang, 2018 .

Randomized Phase 2 Trial of Telitacicept in Patients With IgA Nephropathy With Persistent Proteinuria

Hong Zhang, J. Lv, L. Zuo, 2022, Kidney international reports.

A rationally designed ICAM1 antibody drug conjugate eradicates late-stage and refractory triple-negative breast tumors in vivo

M. Moses, B. Zhu, Jing Huang, 2023, Science advances.

Efficacy and safety of telitacicept in primary Sjögren's syndrome: a randomized, double-blind, placebo-controlled, phase 2 trial.

C. Bao, Wei Wei, Zhijun Li, 2023, Rheumatology.

Disitamab vedotin (RC48) plus toripalimab for HER2-expressing advanced gastric or gastroesophageal junction and other solid tumours: a multicentre, open label, dose escalation and expansion phase 1 trial

Zhi Peng, Xiaotian Zhang, J. Gong, 2024, EClinicalMedicine.

Efficacy and Safety of Disitamab Vedotin in Patients With Human Epidermal Growth Factor Receptor 2–Positive Locally Advanced or Metastatic Urothelial Carcinoma: A Combined Analysis of Two Phase II Clinical Trials

Yanxia Shi, Y. Ling, Lin Wang, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

An open-label, dose-escalation phase I study to evaluate RC48-ADC, a novel antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer.

Bing-he Xu, Jiayu Wang, Wenxiang Wang, 2018 .